Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New Therapies on the Horizon.
Cooper AJ, Heist RS. Cooper AJ, et al. Among authors: heist rs. Hematol Oncol Clin North Am. 2023 Jun;37(3):623-658. doi: 10.1016/j.hoc.2023.02.004. Epub 2023 Apr 5. Hematol Oncol Clin North Am. 2023. PMID: 37029036 Review.
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist RS, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Bent B, de Sauvage MA, Ijad N, Larson JM, Marion B, Nason S, Murthy N, Ratcliff S, Summers EJ, Mahar M, Shih HA, Oh K, Cahill DP, Gerstner ER, Sullivan RJ. Brastianos PK, et al. Among authors: heist rs. Nat Med. 2023 Jul;29(7):1728-1737. doi: 10.1038/s41591-023-02392-7. Epub 2023 Jun 2. Nat Med. 2023. PMID: 37268724 Free PMC article. Clinical Trial.
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B; ANSELMA collaborative group. Remon J, et al. Among authors: heist rs. Eur J Cancer. 2022 May;166:112-125. doi: 10.1016/j.ejca.2022.02.002. Epub 2022 Mar 11. Eur J Cancer. 2022. PMID: 35286903 Review.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, Janne PA, Awad MM. Pecci F, et al. Among authors: heist rs. Cancer Discov. 2024 Apr 3. doi: 10.1158/2159-8290.CD-23-1217. Online ahead of print. Cancer Discov. 2024. PMID: 38564707
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen H, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Corcoran RB, et al. Among authors: heist rs. Clin Cancer Res. 2024 May 1;30(9):1739-1749. doi: 10.1158/1078-0432.CCR-23-3135. Clin Cancer Res. 2024. PMID: 38456660 Free PMC article. Clinical Trial.
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.
Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, Do A, Peterson J, Sequist LV, Gainor JF, Lennerz JK, Digumarthy SR. Dagogo-Jack I, et al. Among authors: heist rs. JTO Clin Res Rep. 2023 Jun 1;4(8):100534. doi: 10.1016/j.jtocrr.2023.100534. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37533439 Free PMC article.
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.
Dagogo-Jack I, Manoogian A, Jessop N, Georgantas NZ, Fintelmann FJ, Farahani A, Digumarthy SR, Price MC, Folch EE, Keyes CM, Do A, Peterson JL, Mino-Kenudson M, Pitman M, Rivera M, Nardi V, Dias-Santagata D, Le LP, Iafrate AJ, Heist RS, Ritterhouse LR, Lennerz JK. Dagogo-Jack I, et al. Among authors: heist rs. JCO Oncol Pract. 2023 Sep;19(9):786-792. doi: 10.1200/OP.23.00031. Epub 2023 Jul 12. JCO Oncol Pract. 2023. PMID: 37437226
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
Negrao MV, Spira AI, Heist RS, Jänne PA, Pacheco JM, Weiss J, Gadgeel SM, Velastegui K, Yang W, Der-Torossian H, Christensen JG, Sabari JK. Negrao MV, et al. Among authors: heist rs. J Clin Oncol. 2023 Oct 1;41(28):4472-4477. doi: 10.1200/JCO.23.00046. Epub 2023 Jun 16. J Clin Oncol. 2023. PMID: 37327468 Free PMC article.
142 results